Program
Letrozole
Also written as “letrozole”, “Letrozole Tablets 2.5 mg” and “Arm C: Gedatolisib + Palbociclib + Letrozole”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Polycystic Ovary Syndrome · Endometrial Neoplasms · Infertility, led by 7 companies.
Drug pageLetrozole: every studyMany companies study it; this page follows only the 38 they lead. All 340 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 280 open or running | phase 4since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jun 13, 2011 | Jun 13, 2011 | none ahead |
| Egymedicalpediaits history only | 21 open or running | phase 1since Apr 9, 2024 | Apr 9, 2024 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | phase 1since Jun 3, 2011 | Jun 3, 2011 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Rovi Pharmaceuticals Laboratoriesits history only | 10 open or running | phase 1since Jan 8, 2018 | Jan 8, 2018 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jan 24, 2008 | Jan 24, 2008 | none ahead |
Also a collaborator on its studies: Gilead Sciences, Pfizer and Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Apr 10, 2001.
- Sep 13, 2005Phase 4 study in Breast NeoplasmsNCT00171847 · 93 enrolled · Germany
- Sep 13, 2005Phase 2 study in Endometrial NeoplasmsNCT00171808 · 26 enrolled · Germany
- Oct 9, 20053 phase 4 studies in Breast NeoplasmsNCT00237224, NCT00237133, NCT00241046
- Oct 9, 20053 phase 2 studiesNCT00237211, NCT00237198, NCT00240942
- Nov 1, 20052 phase 2 studies in Breast NeoplasmsNCT00247663, NCT00247650
- Nov 2, 2005Phase 3 study in Breast NeoplasmsNCT00248170 · 4,172 enrolled · United States, Australia, Austria and more
- May 23, 20065 phase 3 studiesNCT00329940, NCT00330317, NCT00333047 and 2 more
- Jun 1, 2006Phase 2 study in RecurrenceNCT00333086 · 36 enrolled · Germany
- Sep 24, 2007Phase 3 study in Breast NeoplasmsNCT00535418 · 35 enrolled
- May 29, 2008Phase 4 study in Breast NeoplasmsNCT00688909 · 261 enrolled · United States
- Oct 28, 2010Phase 2 study in Breast NeoplasmsNCT01231659 · 72 enrolled · Israel
- Oct 1, 2012Phase 2 study in Breast NeoplasmsNCT01698918 · 202 enrolled · United States, Argentina, Brazil and more
- Feb 15, 2017Phase 2 study in Breast NeoplasmsNCT03056755 · 383 enrolled · United States, Argentina, Belgium and more
- Jan 29, 2018Phase 3 study in Breast NeoplasmsNCT03439046 · 287 enrolled · Italy
TargetBeta
“Cytochrome P450 19A1 inhibitor”ChEMBL 37, by rule
Studies
All 28 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03439046Breast Neoplasms · Italy | 3 | Terminated | Dec 11, 2023 | 287 |
| NCT03056755Breast Neoplasms · United States, Argentina, Belgium and more | 2 | Completed | Jun 14, 2021 | 383 |
| NCT01698918Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Completed | Dec 17, 2015 | 202 |
| NCT01231659Breast Neoplasms · Israel | 2 | Completed | Nov 20, 2012 | 72 |
| NCT00688909Breast Neoplasms · United States | 4 | Completed | Jun 2009 | 261 |
| NCT00535418Breast Neoplasms | 3 | Completed | Jul 2002 | 35 |
| NCT00333086Recurrence · Germany | 2 | Completed | Jun 2006 | 36 |
| NCT00333047Breast Neoplasms · Germany | 3 | Completed | 24 | |
| NCT00332852Breast Neoplasms · Germany | 3 | Completed | Jul 2010 | 655 |
| NCT00332709Osteoporosis · Germany | 3 | Completed | Aug 2010 | 83 |
| NCT00330317Breast Neoplasms · United Kingdom | 3 | Completed | Mar 2010 | 300 |
| NCT00329940Breast Neoplasms · France | 3 | Completed | Jan 2008 | 200 |
| NCT00248170Breast Neoplasms · United States, Australia, Austria and more | 3 | Completed | Sep 2014 | 4,172 |
| NCT00247663Breast Neoplasms · Japan | 2 | Completed | Dec 2005 | 17 |
| NCT00247650Breast Neoplasms · Canada | 2 | Completed | Mar 2007 | 190 |
| NCT00241046Breast Neoplasms | 4 | Terminated | Mar 2005 | 13 |
| NCT00240942Endometriosis | 2 | Completed | Jun 2006 | 40 |
| NCT00237224Breast Neoplasms · Mexico | 4 | Completed | Feb 2007 | 40 |
| NCT00237211Breast Neoplasms · Japan | 2 | Completed | Oct 2006 | 31 |
| NCT00237198Breast Neoplasms · Japan | 2 | Completed | Jul 2006 | 47 |
| NCT00237133Breast Neoplasms · Brazil | 4 | Completed | Jan 2009 | 112 |
| NCT00171847Breast Neoplasms · Germany | 4 | Terminated | Oct 2008 | 93 |
| NCT00171808Endometrial Neoplasms · Germany | 2 | Completed | May 2010 | 26 |
| NCT00171704Breast Neoplasms · Denmark, United Kingdom | 3 | Completed | Mar 2011 | 263 |
| NCT00171340Bone Diseases, Metabolic · Argentina, Australia, Belgium and more | 3 | Completed | Feb 2010 | 1,065 |
| NCT00171314Breast Neoplasms · Argentina, Belgium, France and more | 3 | Completed | Nov 2010 | 527 |
| NCT00050011Breast Neoplasms · United States, Puerto Rico | 3 | Completed | Jan 2009 | 602 |
| NCT00014638Breast Neoplasms · United States | 4 | Completed | Mar 2002 |
How it is read
Names in the registry
- “Letrozole”, 40 entries
- “letrozole”, 6 entries
- “Letrozole Tablets 2.5 mg”, 2 entries
- “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
- “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 37 studies
- Neoplasms, 2 studies
- Polycystic Ovary Syndrome, 2 studies
- Endometrial Neoplasms, 2 studies
- Infertility, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.